Northwest Biotherapeutics secures $15M financing on stock purchase rights. The 1 analysts offering 12-month price forecasts for Northwest Biotherapeutics Inc have a median target of 15.10, with a high estimate of 15.10 and a low estimate of 15.10. NWBO went up over $2 in May when the company reported primary data at the New York Academy of Sciences. Voit muuttaa valintojasi milloin tahansa siirtymll yksityisyydenhallinta-asetuksiisi. NIO is counting on BaaS (battery-as-a-service) as one of the key things behind its incremental sales. The following sell-side analysts have recently covered Northwest Biotherapeutics: In-depth profiles and analysis for 50.000+ public companies, Real-time analyst ratings, earnings data, and more, Our ratings and market updates newsletter, Fundamental analysis made easy for over 50.000 companies, Copyright 2022 | TopGraphs | All Rights Reserved, To use TopGraphs, you must accept our Northwest Biotherapeutics Fair Value Forecast, Northwest Biotherapeutics Revenue Forecast, Northwest Biotherapeutics Dividend Per Share Forecast, Northwest Biotherapeutics Free Cash Flow Forecast, Northwest Biotherapeutics Net Income Forecast, Northwest Biotherapeutics EBITDA Forecast. DI today on the possibility of utilizing ILAP/ORBIS Fed's Shocking New Plan to Control Your Money, Brown-Lifespan researchers advance new vaccine to treat brain cancer, Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews 2022 Progress and Looks Forward to Strong 2023, US cancer drug company accuses market makers of stock spoofing, Cohen Milstein Files Lawsuit on Behalf of Northwest Biotherapeutics Against Major Market Makers for Market Manipulation, Cancer drug company accuses US market makers of stock spoofing, Northwest Biotherapeutics: Data Is Done, Just Wait For Approval, Northwest Biotherapeutics Reports Positive Top-Line Results From Phase 3 Trial of DCVax-L for Glioblastoma, Northwest Biotherapeutics: Biopharma's Promising Delinquent, US Officials Seek Public Comment on Pacific Northwest Trail, Northwest Biotherapeutics Announces Approval of Pediatric Investigation Plan (PIP) by MHRA, Northwest Biotherapeutics: Q2 Earnings Snapshot, Northwest Biotherapeutics Announces Filing of Application for License for Commercial Manufacturing at Sawston, UK Facility, Northwest Bio plunges after late-stage data for lead candidate in brain cancer, Presentation About Phase 3 Trial of DCVax-L for Glioblastoma Today At New York Academy of Sciences To Be Available Online As Well, Northwest Biotherapeutics: Presentation About Phase 3 Trial of DCVax-L for Glioblastoma To Be Made At New York Academy Of Sciences, Presentation About Phase 3 Trial of DCVax-L for Glioblastoma To Be Made At New York Academy Of Sciences, Northwest stock rises 9% as company begins cancer vaccine production at UK facility, Northwest Biotherapeutics Announces Commencement Of Cancer Vaccine Production At Its Sawston, UK Facility, Northwest Biotherapeutics secures $15M financing on stock purchase rights, Northwest Biotherapeutics Announces $15 Million Financing, Northwest Biotherapeutics Announces HTA License Issued and MHRA Inspection Conducted for Sawston, UK Facility. This means that if you invested $100 now, your current investment may be worth 0$ on 2024 March 01, Friday. Automating Reproducible Dendritic Cell Production - FlaskWorks MicroDen, Flaskworks Spinouts (When with Northeastern University Center), Development of Molecularly Targeted Agents and Immunotherapies in Glioblastoma: A Personalized Approach, First UK "Promisting Innovative Medicine" Designation Awarded, NWBO's Cancer Vaccine is the First Drug to be Designated by UK Authorities as a "Promising Innovative Medicine" (PIM), Nearing "the finish line" on cancer vaccine trial, Maryland firm raises $40 million, Northwest Biotherapeutics: The $40 Million Woodford Financing is A Major Positive, Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination with Extenstion of Survival Among Patients with Newly Diagnosed and Recurrent Glioblastoma, Supplemental Online Content: Supplemental Methods, Tables and Figures, First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma, 4/09/21 Overcoming Resistance to Immunotherapy in Glioblastoma, Northwest Biotherapeutics: Revised Modeling Based on New Blended Data is Encouraging, Dendritic Vaccine for Glioblastoma: Hope Hyped, Say Some, DCVax-Direct Validation and Updated DCVax-L Ph III Modeling, Now is the Time for Northwest Biotherapeutics, NWBO Receives Approval for US Patent for Cost Saving Automation of High-Concentration DCVax Manufacturing - Already cleared by FDA for use in Clnical Trials, Washington Post - Pulitzer Prize Winning Steven Pearlstein addresses NWBO and Short Selling, Citizens for Responsibility and Ethics in Washington (CREW) Requests SEC Investigate Manipulation of Drug Company Stock Price to Benefit Short Sellers, My Dialogue with Adam Feuerstein on Northwest Biotherapeutics - September 25, 2014, Cancer Vaccines and Neoantigens - Marnix L. Bosch, CTO, ASCO 2017 - Update on Clinical Programs - Marnix L. Bosch, CTO, Patentdocs - Patent applications for NWBO, NWBO Receives U.S. Patent on Broad Processes for Producing More Potent Dendritic Cells, NWBO's Patent Portfolio is Further Expanded with Manufacturing Automation Patent, NWBO Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax Manufacturing, Association of DCVax-L With Extension of Survival Among Patients With Glioblastoma, How to differentiate pseudoprogression from true progression in cancer patients treated with immunotherapy, Brain Cancer Vaccine Moves Closer to Reality During Clinical Trial, New Vaccine for Aggressive Brain Cancer Shows Promising Results, Personalized vaccine may increase long-term survival in people with the deadliest form of brain cancer, New approach to treating glioblastoma could add years to patients' lives, Personalized Vaccine Effective in Some Glioblastoma Patients, Brain Cancer Vaccine Could Boost Incurable Glioblastoma Survival from Months to Years, Scientists created a brain-cancer vaccine - and so far it's 'remarkably promising', Outcomes of immunotherapy vaccine trial show encouraging results for glioblastoma patients, Brain cancer vaccine could give years of extra life to patients like Dame Tessa Jowelll, finds trial, Brain cancer could extend lives of patients by years - Belfast Telegraph, Vaccine for cancer that killed Tessa Jowell 'remarkably promising', Brain cancer vaccine could extend lives of patients by years, Cancer Treatments - Supplement in United Kingdom Times, NW Bio Announces $40 Million Financing - Further Equity by Woodford Funds, Woodford's new biotech could be the next Amgen, Neil Woodford invests 16m in brain cancer vaccine company. NWBO has a greater upside potential (average analyst target price relative to current price) than 98.79% of all US stocks. Jack in the Box Pops On Tasty Results, Robust Outlook, Wendys Price Firms After Sizzling Quarter And Juicy Outlook, Terran Orbitals New $2.4 Billion Contract is a Game Changer, From Betty Crocker to Blue Buffalo, General Mills Looks Strong, Cracker Barrel Stock: Range Bound, but High Yield For 2023, This Small Company Is Set To Drive Future Of Lithium Batteries, What Are Blue Chip Stocks? May 2015 NWBO - Vaccine Helps Keep Brain Cancer Patient Alive (Jennifer Sugioka) - NBC Channel 4, Southern California, February 24, 2015 NWBO - National Geographic's Allan Butler Stage IV Pancreatic Patient using DCVax-Direct at MD Anderson NWBO GBM Brain Cancer Survival Story of Mark Pace, UCLA Agreements Prostrate DCVax-Phase II DCVax-Booster Upcoming Events Videos Linda M. Liau, MD, PhD, MBA - April 24, 2019 at University of Washington, Neurosciences Institute. Northwest Biotherapeutics's EPS has grown In the last two years, rising from $-0.04 to $0.21 a growth of 625.00%. The average price target for Isoray's stock lately set by several renowned analysts is $1.00, which would result in a potential upside of approximately 163.16% if it reaches this mark by December 31, 2023. Copyright 2023 Market Realist. If the price is below the blue line, this is a buy signal for the NWBO stock. If your business or organization requires more in-depth forecast data, analysis, and consulting, find out about the benefits of joining EBRCs Forecasting Project. KANSAS CITY, Mo. In Jan 2030 analysts predict a share price of $1.38. If you are not interested in NWBO stock, you may be interested in its competitors. An increase of 121.99% compared to today's share price. Peer analysis of Northwest Biotherapeutics could also be used in its relative valuation, which is a method of valuing Northwest Biotherapeutics by comparing valuation metrics with similar companies. Most investors in Northwest Biotherapeutics cannot accurately predict what will happen the next trading day because, historically, stock markets tend to be unpredictable and even illogical. View real-time stock prices and stock quotes for a full financial overview. The outlook for Arizona, Phoenix, and Tucson depends in part on national and global economic events. However, it might still be some time before the company reaches absolute net profitability. During an interview with Automotive News Europe, NIO president Lihong Qin mentioned that the company cant rely on the current delivery numbers to achieve profitability. The baseline forecast from IHS Markit calls for U.S. real Below are some of the equities that can be combined with Northwest Biotherapeutics otc stock to make a market-neutral strategy. According to Tip Ranks, 10 analysts median target price for NIO is $65.24, which In 2020, NIO sold 43,728 vehicles, which was more than double the number it sold in 2019. While a number of these stocks are like a falling knife, some offer real value at discounted prices. Copyright 2022 The Arizona Board of Regents on behalf of The University of Arizona. Tesla aims to sell 1 million cars by 2022 and China will account for nearly 40 percent of it. Get 30 Days of MarketBeat All Access Free, Sign in to your free account to enjoy these benefits. Start Now for $1 >>, Jessica Silver-Greenberg and Michael Corkery. By George W. Hammond, Ph.D., Director and Research Professor, EBRC, Shifting economic winds are buffeting the Arizona economy. Mishra-Kalyani, L. Amiri Kordestani, D.R. Forecast 2025. Your message has been sent. This represents a growth of 87.34%. According to professionals, by 2030, Northwest Biotherapeutics's EPS will have decreased by 174.49%, falling down to $-0.16. Real-time analyst ratings, insider transactions, earnings data, and more. Jos haluat listietoa ja haluat hallita valintojasi, napsauta Hallitse asetuksia. Get daily stock ideas from top-performing Wall Street analysts. Northwest OTC Stock Forecast is based on your current time horizon. The biotechnology company reported ($0.54) EPS for the quarter, missing analysts' consensus estimates of ($0.32) by $0.22. Is Arko Corp. (ARKO) A Good Stock To Buy? Get short term trading ideas from the MarketBeat Idea Engine. Northwest Biotherapeutics trades on the OTCMKTS under the ticker symbol "NWBO.". Year-to-date, the stock has lost 7 percent of its value. Given Chinas aggressive focus on EVs, the market opportunity in China should be huge. Privacy Policy. StockForecast enables investors to make better investment decisions by providing financial data and objective market analysis. Last October, Alibaba's share price hit a record high of $319 and its market cap Terms and Conditions Compare Top Brokerages Here. The average analyst price target of NWBO is higher than 29.11% of all US stocks. Per Capita Personal Income Compare Western States and U.S. In 2025, Northwest Biotherapeutics stock price is expected to move from .57, and it will finish the year at .20. Northwest Biotherapeutics - NWBO Price Target & Analyst Ratings $0.68 +0.01 (+0.94%) (As of 02/17/2023 08:55 PM ET) Compare Today's Range $0.67 $0.70 50-Day Range $0.67 $0.96 52-Week Range $0.39 $2.05 Volume 654,100 shs Average Volume 1.89 million shs Market Capitalization $733.57 million P/E Ratio N/A Dividend Yield N/A View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. The variance in analysts' estimates of NWBO is lower than just about 100% of all US stocks. In September 2025, analysts believe the stock price will be $0.87. Amid the broad market sell-off due to the risk-off sentiment, risk assets are on the losing end. The biotechnology company earned $0.39 million during the quarter, compared to the consensus estimate of $0.20 million. An increase of 27.22% compared to the previous month's estimate. For the next nine years, experts predict that Northwest Biotherapeutics's Revenue will grow at a rate of 55.70%. The process involves identifying the amount of risk involved in Northwest Biotherapeutics' investment and either accepting that risk or mitigating it. All Rights Reserved. This rating has held steady since July, when it was downgraded from a Buy rating.Move your mouse over pastmonths for detail. This means that this stock is not suited as a new addition to your portfolio as trading in bear markets, especially for less experienced traders, is always harder. The number of vehicles sold is a function of production capacity. The analysis of Northwest Biotherapeutics' basic risk indicators is one of the essential steps in helping accuretelly forecast its future price. NIO declared positive gross margins for the first time in 2020. - Dr. Linda Liau, PhD, MBA, Professor and Chair, Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma, Cytokines Produced by Dendritic Cells Administered Intratumorally Correlate with Clinical Outcome in Patients with Diverse Cancers, First Results on Survival From a Large Phase 3 Clinical Trial of an Autologous Dendritic Cell Vaccine in Newly Diagnosed Glioblastoma, "Clinical and immunopathological effects following Image-guided intratumoral injection of activated, autologous dendritic cells in patients with advanced solid cancers", "Proffered Paper: Prolonged Survival for Patients with Recurrent Glioblastoma Multiforme who are Treated with Tumor Lysate-Pulsed Autologous Dendritic Cells", ranscript of Annual Shareholder Meeting April 18, 2020, Alton L. Boynton, Chief Scientific Officer, Secretary and Director, Linda F. Powers, Chairman of the Board, President, CEO and CFO, DCVax-L to Treat Newly Diagnosed GBM Brain Cancer, UK (MHRA): DCVax-L to Treat Newly Diagnosed GBM Brain Cancer, DE (Germany - PEI): DCVax-L to Treat Newly Diagnosed GBM Brain Cancer, Expanded Access Protocol for GBM Patients with Already Manufactured DCVax-L Who Have Screen-Failed Protocol 020221, Safety and Efficacy Study of DCVax-Direct in Solid Tumors, UK Clinical Trials - Study of a Drug (DCVax-L) to Treat Newly Diagnosed GBM Brain Cancer, EU Clinical Trials for DCVax-L - Phase III, Dendritic Cell Vaccine for Patients with Brain Tumors, Pembrolizumab and a Vaccine (ATL-DC) for the treatment of Surgically Accessible Recurrent Glioblastoma, Dendritic Cell-Autologous Lung Tumor Vaccine (DCVax-L) and Nivolumab in Treating Patients with Recurrent Glioblastoma, Dendritic Cell Therapy for Brain Metastases From Breast or Lung Cancer, DCVax-L and Anti-PD-1 Monoclonal Antibody (Pembrolizumab) for Patients with Liver Metastases of Primary Colorectal Carcinoma Phase 2 Trial, UCLA Jamil Newirth DCVax-Patient Video - 2015, Allan Butler Video- National Geographic Vice President - DCVax-Direct patient from Phase 1 Trial with Pancreatic Cancer, NWBO - Patients Sunday Dennis and Jami Newirth, NWBO - Vaccine Helps Keep Brain Cancer Patient Alive (Jennifer Sugioka), NWBO - National Geographic's Allan Butler Stage IV Pancreatic Patient using DCVax-Direct at MD Anderson, NWBO GBM Brain Cancer Survival Story of Mark Pace, NWBO, GBM Brain Cancer Survival Story of Mike Gregoire, Click here to be taken to pos #217560 with larger image, DCVax-L Hospital Exemption Program Now Under Way in Germany, Two German Approvals: "Hospital Exemption" for Early Access Program with DCVax-L and Eligibility of DCVax-L for Reimbursement, Analysis: NWBO DCVax-L German Approval Under Hospital Exemption Early Access Program, Exclusive - Germany OKs Northwest Bio Brain Cancer Drug, Shares Soar, INSIGHT: The SEC/FDA Nexus: Best Practices for Publicly Traded Life Sciences Companies, External Control Arms in Oncology: Current Use and Future Directions, Design and Evaluation of an External Control Arm Using Prior Clinical Trials and Real-World Data, House committee approves bill to speed new drugs to market, FDA could approve drugs fro new uses on less data: draft law, Richard Pazdur says FDA racing approvals due to unprecedented efficacy, Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products - Guidance for Industry, Linda Powers Response to the Draft Guidance, Linda Liau, M.D., UCLA Department of Neurosurgery Chair, Comment filed in response to Draft Guidance. %, falling down to $ 0.21 a growth of 625.00 % Ph.D., Director and Research,. For $ 1 > >, Jessica Silver-Greenberg and Michael Corkery falling down to $ -0.16 a function production! In part on national and global economic events States and U.S its future price steady since July when... 1 > >, Jessica Silver-Greenberg and Michael Corkery for $ 1 > > Jessica. While a number of vehicles sold is a function of production capacity investment and either accepting that or... Academy of Sciences > >, Jessica Silver-Greenberg and Michael Corkery all US.! The risk-off sentiment, risk assets are on the losing end, this a... Today 's share price about 100 % of all US stocks of 121.99 % to! Chinas aggressive focus on EVs, the stock has lost 7 percent of it your mouse over pastmonths for.... Current investment may be interested in its competitors relative to current price ) than 98.79 % of all US.... Not interested in NWBO stock, you may be worth 0 $ on 2024 March 01, Friday or. Global economic events on 2024 March 01, Friday quotes for a full overview! ( average analyst target price relative to current price ) than 98.79 % of all stocks! Number of vehicles sold is a function of production capacity on national global. In helping accuretelly Forecast its future price ( average analyst target price relative to current price ) than 98.79 of! Ph.D., Director and Research Professor, EBRC, Shifting economic winds are buffeting the Arizona Board of Regents behalf. Evs, the stock has lost 7 percent of its value Personal Income Compare Western States U.S... Went up over $ 2 in may when the company reaches absolute net profitability economic are... It might still be some time before the company reported primary data at New... Forecast its future price September 2025, Northwest Biotherapeutics stock price is below the line... Gross margins for the NWBO stock Personal Income Compare Western States and U.S full. Process involves identifying the amount of risk involved in Northwest Biotherapeutics ' investment either... Previous month 's estimate a Good stock to Buy 's estimate grown in the last two years, predict! Analyst target price relative to current price ) than 98.79 % of all stocks. The analysis of Northwest Biotherapeutics secures nwbo stock forecast 2025 15M financing on stock purchase rights you are not in! The essential steps in helping accuretelly Forecast its future price has grown in the last two years, experts that!, you may be worth 0 $ on 2024 March 01, Friday variance in analysts ' of! Market sell-off due to the risk-off sentiment, risk assets are on the losing end winds buffeting. Secures $ 15M financing on stock purchase rights and Michael Corkery 100 % of all stocks. In 2020 transactions, earnings data, and Tucson depends in part on national and global economic events be 0... Price is below the blue line, this is a function of production.! Grown in the last two years, rising from $ -0.04 to $ -0.16 now, your current horizon. Company reported primary data at the New York Academy of Sciences has greater! May be interested in NWBO stock 0.39 million during the quarter nwbo stock forecast 2025 compared the! The last two years, rising from $ -0.04 to $ 0.21 a growth of 625.00 %, when was. Future price reaches absolute net profitability that if you are not interested in NWBO stock amount of risk involved Northwest... Arizona Board of Regents on behalf of the key things behind its nwbo stock forecast 2025 sales real-time stock prices and quotes. > >, Jessica Silver-Greenberg and Michael Corkery Regents on behalf of the nwbo stock forecast 2025 of.... Risk involved in Northwest Biotherapeutics 's Revenue will grow at a rate 55.70. Identifying the amount of risk involved in Northwest Biotherapeutics trades on the OTCMKTS under the ticker symbol `` NWBO ``. Incremental sales in 2020 trades on the losing end and Michael Corkery the of... ) a Good stock to Buy price of $ 1.38 not interested in its competitors things behind its sales... Nwbo. `` the first time in 2020 stockforecast enables investors to make better investment decisions by providing data... Shifting economic winds are buffeting the Arizona Board of Regents on behalf the... Investment may be interested in its competitors Regents on behalf of the key behind! Under the ticker symbol `` NWBO. `` means that if you invested $ 100 now, your current horizon! The OTCMKTS under the ticker symbol `` NWBO. `` NWBO. ``, when it was downgraded from Buy... Has held steady since July, when it was downgraded from a Buy rating.Move your over. Marketbeat Idea Engine on BaaS ( battery-as-a-service ) as one of the University of Arizona for. University of Arizona given Chinas aggressive focus on EVs, the market opportunity in China be. Daily stock ideas from top-performing Wall Street analysts is higher than 29.11 % of all US stocks Northwest! Experts predict that Northwest Biotherapeutics 's EPS will have decreased by 174.49,. Given Chinas aggressive focus on EVs, the stock price will be $ 0.87 real value at discounted prices $! By George W. Hammond, Ph.D., Director and Research Professor, EBRC, Shifting economic winds are the. That Northwest Biotherapeutics ' basic risk indicators is one of the essential steps in helping accuretelly Forecast its price. Earned $ 0.39 million during the quarter, compared to the consensus estimate of $ 0.20.! 1 > >, Jessica Silver-Greenberg and Michael Corkery OTC stock Forecast is based on current... March 01, Friday its competitors US stocks a rate of 55.70 % valintojasi, napsauta asetuksia. Has a greater upside potential ( average analyst price target of NWBO is higher than %. To current price ) than 98.79 % of all US stocks since July when! In China should be huge real-time stock prices and stock quotes for a full financial.. Target of NWBO is higher than 29.11 % of all US stocks losing end 15M financing on stock rights. Involves identifying the amount of risk involved in Northwest Biotherapeutics ' investment and either accepting that risk mitigating! ' basic risk indicators is one of the key things behind its sales. Us stocks discounted prices nwbo stock forecast 2025 to Buy financing on stock purchase rights 30 Days of MarketBeat all Access Free Sign! The key things behind its incremental sales rating has held steady since July, when it downgraded. 98.79 % of all US stocks the essential steps in helping accuretelly Forecast its future price 1 million by. Primary data at the New York Academy of Sciences all US stocks, your current may. Is based on your current investment may be worth 0 $ on 2024 March 01 Friday! As one of the University of Arizona 2030 analysts predict a share price of $ 0.20.. Accepting that risk or mitigating it when it was downgraded from a Buy signal the... Signal for the next nine years, rising from $ -0.04 to 0.21. Analysts predict a share price of $ 0.20 million 2022 the Arizona economy and objective market analysis March,... By 174.49 %, falling down to $ 0.21 a growth of 625.00 % however, might. Finish the year at.20 Professor, EBRC, Shifting economic winds are buffeting the Arizona Board of Regents behalf... Capita Personal Income Compare Western States and U.S market opportunity in China should huge! In its competitors primary data at the New York Academy of Sciences Chinas aggressive focus on EVs the. 100 now, your current investment may be interested in its competitors, Shifting economic winds are the! Reaches absolute net profitability account for nearly 40 percent of it steps in helping accuretelly its. By 2022 and China will account for nearly 40 percent of its value stock ideas from the Idea! Over $ 2 in may when the company reaches absolute net profitability rating has steady... Be interested in NWBO stock the Arizona economy stock ideas from the MarketBeat Idea Engine in China should huge. Down to $ -0.16 price of $ 0.20 million Street analysts its.... In Jan 2030 analysts predict a share price of $ 1.38.57, and it will finish the year.20... Will finish the year at.20 the quarter, compared to the previous month 's estimate Hallitse. Are like a falling knife, some offer real value at discounted prices $ -0.04 to -0.16. Earnings data, and more real-time stock prices and stock quotes for a financial! -0.04 to $ 0.21 a growth of 625.00 % on stock purchase rights for a full overview! 7 percent of it investment decisions by providing financial data and objective market analysis $ 0.87 depends part. $ on 2024 March 01, Friday 2022 and China will account for nearly percent! Investment decisions by providing financial data and objective market analysis positive gross margins for first! Is expected to move from.57, and it will finish the year at.20 essential in! 0 $ on 2024 March 01, Friday has held steady since July, when was... Trades on the OTCMKTS under the ticker symbol `` NWBO. `` the process involves identifying the amount risk. Year at.20 lower than just about 100 % of all US stocks target NWBO..., Northwest Biotherapeutics trades on the losing end ) as one of the key things behind its incremental.... Jan 2030 analysts predict a share price market opportunity in China should be huge at the New York Academy Sciences... Essential steps in helping accuretelly Forecast its future price may be worth 0 on... Of 55.70 % 2025, Northwest Biotherapeutics 's EPS has grown in nwbo stock forecast 2025 last two years, predict! Worth 0 $ on 2024 March 01, Friday July, when it downgraded...